Analyst Price Targets — TLSI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 15, 2024 12:04 pm | William Plovanic | Canaccord Genuity | $11.00 | $4.11 | StreetInsider | TriSalus Life Sciences, Inc. (TLSI) PT Lowered to $11 at Canaccord Genuity |
| September 16, 2024 6:06 am | Suraj Kalia | Oppenheimer | $10.00 | $4.52 | StreetInsider | Oppenheimer Starts TriSalus Life Sciences, Inc. (TLSI) at Outperform, PT $10 |
| July 2, 2024 5:51 am | William Plovanic | Canaccord Genuity | $12.00 | $5.33 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI) |
Latest News for TLSI
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026.…
TriSalus Life Sciences, Inc. (NASDAQ: TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the firm's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $4.13, for a total value of $17,998.54. Following the completion of the transaction, the chief executive officer owned 768,931 shares
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models…
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TLSI.
U.S. House Trading
No House trades found for TLSI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.